Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on TG4010

le
0
Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on TG4010

- ?96.2 million in cash and cash equivalents as of June 30, 2014
- Updated TG4010 data show an improvement in overall survival consistent with improvement in progression-free survival as previously reported
- Updated TIME trial results in advanced non-small cell lung cancer to be presented at ESMO 2014 Congress

Strasbourg, France, September 8, 2014 - Transgene (Euronext Paris: TNG) today announced its financial results for the six-month period ended June 30, 2014 and provided an update on one of its lead development programs, TG4010 MUC-1 targeted cancer immunotherapy.

Key highlights of the Interim Financial Report are as follows:

- Stable operating revenue and expenses, with ?6.3 million in revenue and ?26.0 million in R&D expenses for the six-month period.

- Net loss (?25.1 million) and cash burn (?14.8 million) in line with budget, with no deviation expected in cash burn guidance for the full year 2014 (?50-55 million).

- Solid cash position: ?96.2 million as of June 30, 2014.

Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.

Pour consulter le fichier PDF en intégralité, cliquez ici.

Pour visualiser les documents au format PDF, vous pouvez télécharger gratuitement Acrobat Reader XI.


Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant